Access Advance Announces New Effective Discount Rates for Its Multi-Codec Bridging Agreement, Starting on January 1, 2027
11.11.2026 20:18:00 CET | Business Wire | Press Release
Access Advance LLC today announced that the Licensors of the HEVC Advance and VVC Advance Patent Pools have independently approved a two-step, phased reduction in the effective royalty discount available under the Multi-Codec Bridging Agreement (MCBA) for Licensees of both pools who sign the MCBA on or after January 1, 2027. Licensees that join both the HEVC Advance and VVC Advance Patent Pools and execute the MCBA on or before December 31, 2026, will secure the current MCBA rates, resulting in an effective discount of up to 50%. Licensees that sign on or after January 1, 2027 will receive a reduced discount as further described below.
The MCBA is an administrative agreement, not a separate license, that lets Licensees of both HEVC Advance and VVC Advance Patent Pools pay a single, reduced royalty rate for products that include both HEVC and VVC codecs. Today the MCBA rate for a dual-codec product is the same as the VVC Advance single codec product rate; up to 50% of what a Licensee would pay under the two pool licenses separately.
With the upcoming change in the discount rates, the size of the effective MCBA discount for a given Licensee will depend both on when the Licensee joins both pools and when it signs the MCBA. The MCBA discount will be as follows:
- Up to 50% for Licensees that join both pools and execute the MCBA on or before December 31, 2026
- Up to 40% for Licensees that join both pools and execute the MCBA from January 1, 2027, through June 30, 2027
- Up to 25% for Licensees that join both pools and execute the MCBA on or after July 1, 2027
Current Licensees who have already signed an MCBA are not affected by this change and will keep their existing rates.
As an example, for a mobile device with both HEVC and VVC codecs in Region 1, the current HEVC Advance and VVC Advance stand-alone rates would total $1.00 per unit ($0.50/unit to each pool). Under the MCBA, that same mobile device carries a royalty of $0.50 for Licensees that sign by December 31, 2026, $0.60 for those that sign in the first half of 2027, and $0.75 for those that sign on or after July 1, 2027.
The rates for all device types are below:
Existing HEVC Licensees (On or Before June 30, 2026) | HEVC Licensees (After June 30, 2026) | VVC Licensees (All) | Current MCBA (On or Before December 31, 2026) | New MCBA Phase 1 (On or Before June 30, 2027) | New MCBA Phase 2 (After June 30, 2027) | |
Mobile Devices | R1: $0.40 R2: $0.20 | R1: $0.50 R2: $0.25 | R1: $0.50 R2: $0.25 | R1: $0.50 R2: $0.25 | R1: $0.60 R2: $0.30 | R1: $0.75 R2: $0.375 |
Connected Home & Other Devices | R1: $0.80 R2: $0.40 | R1: $1.00 R2: $0.50 | R1: $1.00 R2: $0.50 | R1: $1.00 R2: $0.50 | R1: $1.20 R2: $0.60 | R1: $1.50 R2: $0.75 |
4K UHD+ Television/Display | R1: $1.20 R2: $0.60 | R1: $1.50 R2: $0.75 | R1: $1.50 R2: $0.75 | R1: $1.50 R2: $0.75 | R1: $1.80 R2: $0.90 | R1: $2.25 R2: $1.125 |
Content on Digital Media Storage | R1: $0.0225 R2: $0.01125 | R1: $0.028 R2: $0.014 | R1: $0.028 R2: $0.014 | R1: $0.028 R2: $0.014 | R1: $0.0336 R2: $0.0168 | R1: $0.042 R2: $0.021 |
All rates shown reflect the In-Compliance rates with the trademark discount in each category.
The royalty caps under the MCBA are not changing. Licensees having the MCBA also continue to receive simplified reporting, invoicing and payment, a single patent marking notice and trademark logo that satisfy both pool licenses, a 20% limit on rate and cap increases per renewal term, and license terms that are certain through 2035.
"For five years, the MCBA has given companies that build, or plan to build, products with both HEVC and VVC a single, lower-cost way to license the two codecs together," said Peter Moller, CEO of Access Advance. "While the MCBA discount is being moderately reduced, it remains significant. As more products add VVC alongside HEVC, companies that have not yet joined both pools and signed the MCBA have until the end of the year to secure the current discount."
Companies interested in the HEVC Advance Patent Pool, the VVC Advance Patent Pool and the MCBA can contact Access Advance at licensing@accessadvance.com. Current rate information is available at accessadvance.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261111197306/en/
Contacts
Media Contact:
Meredith Hollander
Director, Strategic Communications
Access Advance LLC
Email: press@accessadvance.com
Website: www.accessadvance.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.accessadvan
ce.com&esheet=54639732&newsitemid=20261111197306&lan=en-US&anchor=www.accessadva
nce.com&index=1&md5=3b413ec83aa0a6e06e451913596d7e2d
Licensing Inquiries:
Email: licensing@accessadvance.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press Release
Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bindu Saran, VP of Product Strategy, added: “Angel was founded by orthodontic profe
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press Release
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio. Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and inn
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press Release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press Release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press Release
Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an outcome. End customers for Epinal’s SEB include breathalyzer manufacturers, healthcare, mobile computers & clinical smartphones, handheld bio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom